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Abstract: Coronary heart disease is a global malady and it is the leading cause of death in the United States. Chronic stable angina is 
the most common manifestation of coronary heart disease and it results from the imbalance between myocardial oxygen supply and 
demand due to reduction in coronary blood flow. Therefore, in addition to lifestyle changes, commonly used pharmaceutical treatments 
for angina (nitrates, β-blockers, Ca2+ channel blockers) are aimed at increasing blood flow or decreasing O2 demand. However, patients 
may continue to experience symptoms of angina. Ranolazine is a relatively new drug with anti-anginal and anti-arrhythmic effects. Its 
anti-anginal mechanism is not clearly understood but the general consensus is that ranolazine brings about its anti-anginal effects by 
inhibiting the late Na+ current and the subsequent intracellular Ca2+ accumulation. Recent studies suggest other effects of ranolazine that 
may explain its anti-anginal and anti-arrhythmic effects. Nonetheless, clinical trials have proven the efficacy of ranolazine in treating 
chronic angina. It has been shown to be ineffective, however, in treating acute coronary syndrome patients. Ranolazine is a safe drug 
with minimal side effects. It is metabolized mainly in the liver and cleared by the kidney. Therefore, caution must be taken in patients 
with impaired hepatic or renal function. Due to its efficacy and safety, ranolazine was approved for the treatment of chronic angina by 
the Food and Drug Administration (FDA) in 2006.
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Introduction
Cardiovascular diseases are the number one cause of 
death globally. According to the World Health Orga-
nization, an estimated 17.3 million people died from 
cardiovascular diseases in 2008, representing 30% of 
all global deaths. Of these deaths, an estimated 7.3 mil-
lion were due to coronary heart disease.  Coronary 
heart disease, along with stroke, is projected to remain 
the single leading cause of death in the future. Chronic 
stable angina is the most prevalent manifestation of 
coronary artery disease (CAD) with an incidence of 
320,000 cases in males and 180,000 cases in females 
every year in the US.1 Stable angina is a clinical syn-
drome characterized by discomfort in the chest, jaw, 
shoulder, back, or arms, typically elicited by exertion or 
emotional stress and relieved by rest or nitroglycerin,2 
and it is caused by an imbalance between myocardial 
oxygen supply and myocardial oxygen consumption. 
Management of chronic stable angina includes lifestyle 
changes (eg, eating a heart-healthy diet, lowering cho-
lesterol, getting regular exercise, cessation of smok-
ing, and controlling diabetes and high blood pressure), 
pharmacological treatment (β-blockers, Ca2+ channel 
blockers, nitrates, and antiplatelet medications), and 
revascularization procedures when indicated (percu-
taneous coronary intervention (PCI), coronary artery 
bypass grafting).2 Despite the effectiveness of the cur-
rent management strategies, episodes of angina may 
still persist or even worsen3,4 and many patients can-
not tolerate a combination of anti-anginal drugs due 
to their many side effects. Therefore, a new treatment 
that provides an alternative option for patients who 
continue to suffer from symptoms of angina despite 
using other anti-anginal drugs would be helpful. 
Ranolazine is a relatively new drug for the treatment 
of chronic angina that was approved by the Food and 
Drug Administration (FDA) and has been in use in the 
US since 2006.
Metabolism and Pharmacokinetic 
Profile
Ranolazine is a racemic mixture, chemically described 
as 1-piperazineacetamide, N-(2,6-dimethylphenyl)-4-
[2-hydroxy-3-(2-methoxyphenoxy)propyl], with the 
empirical formula of C
24
H
33
N
3
O
4
.5 It contains two 
enantiomeric forms (S-ranolazine and R-ranolazine).6 
Ranolazine was initially manufactured in an imme-
diate-release formulation but it was discontinued 
due to the short elimination half life.7 Ranolazine 
is currently manufactured by Gilead Sciences in an 
extended (sustained)-release tablets of 500 mg and 
1000 mg for clinical use and it is sold under the trade 
name Ranexa®. It is extensively absorbed after oral 
administration and it reaches peak plasma concentra-
tions within 2–5 hours5,7 after a single dose where it 
binds mainly to α-1 acid glycoprotein and weakly to 
albumin. With a dose of 500–1000 mg given twice 
daily, the peak to trough difference is only 1.6 fold. 
Steady state is usually reached within 3 days of mul-
tiple dosing. The half-life of ranolazine at steady state 
after oral administration is nearly 7 hours. Less than 
5% of ranolazine is excreted unchanged by the kid-
ney while the remainder is extensively and rapidly 
metabolized mainly by CYP3A4 enzymes in the liver 
and, to a lesser extent, by CYP2D6. Following a sin-
gle oral dose of ranolazine, total elimination is 75% 
in urine and 25% in feces. These pharmacokinetics 
are not affected by age, gender, or food.5
Mechanism of Action
Although the precise mechanisms for the anti-anginal 
effects of ranolazine are not well understood, several 
pharmacological activities of ranolazine have been 
described. Of these, two distinct mechanisms appear 
to primarily promote its cardiac protection against 
ischemic injury. These include its effect as a meta-
bolic modulator and as a late Na+ current inhibitor. 
Therefore, in this section we will summarize the find-
ings of the many studies in which attempts were made 
to elucidate the mechanism of action of ranolazine. 
Table 1 summarizes some of the mechanisms of rano-
lazine that could be responsible for its anti-anginal 
effects.
ranolazine as a metabolic modulator
In general, drugs such as β-blockers, Ca2+ channel 
blockers, and long acting nitrates exert their anti-
 anginal effects by causing hemodynamic changes 
such as drop in blood pressure, heart rate, and/
or contractility which decreases cardiac work.8 On 
the other hand, ranolazine as many trials showed, 
does not have any clinically significant effect on 
these hemodynamic parameters.9–14 Initially it was 
reported that ranolazine was effective as an anti-
anginal drug by acting as a metabolic modulator.15 
For this mechanism, ranolazine was proposed to 
ranolazine and chronic stable angina
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Table 1. A summary of the possible mechanisms of ranolazine as an anti-anginal drug.
Mechanism Details Notes
Effects on  
metabolism
•  ranolazine increases the amount of active  
dephosphorylated pyruvate dehydrogenase
•  ranolazine stimulates glucose oxidation  
at the expense of fatty acid oxidation
•  Concentration . 10 μM  
(higher than used in clinical settings)
•  This mechanism suggests an  
intra-mitochondrial effect
Effects on late  
Na+ current (INaL)
•  ranolazine inhibits INaL and therefore  
reduces Na+ overload during ischemia
•  This reduces cytosolic Ca2+ overload that occurs by  
activation of Na+/Ca2+ exchanger in the reverse mode
•  This also reduces mitochondrial Ca2+ overload
•  ranolazine inhibits INaL with an 
IC50 = 5.9 μM (within the clinical range)
•  ranolazine inhibits INaL possibly  
by inhibiting the mechano-sensitivity  
of Nav1.5
Effects on  
mitochondrial  
complex I
•  ranolazine inhibits mitochondrial complex I
•   Ranolazine reduces electron flow  
to complex III during ischemia
•  ranolazine reduces mitochondrial  
free radical generation
•  ranolazine is a weak inhibitor  
of complex I in coupled mitochondria
•  ranolazine becomes more potent  
as a complex I blocker in uncoupled  
or broken mitochondria
Effects on  
myofilaments  
Ca2+ sensitivity
•   Ranolazine modulates myofilament  
cross-bridge kinetics and sensitivity to Ca2+
•  ranolazine improves diastolic function  
at the cardiomyocyte level
•   The effects on myofilaments are  
achieved with concentrations  
of ranolazine within the clinical range
stimulate glucose  oxidation at the expense of fatty 
acid  oxidation. Under non-ischemic conditions, myo-
cytes ATP requirement is met by both glucose and 
fatty acid oxidation with the majority (about 90%) 
coming from fatty acid oxidation.16 Fatty acid oxida-
tion is more efficient, energy-wise, than glucose oxi-
dation in ATP production. However as the supply of 
O2 dwindles during ischemia, glucose becomes the 
preferred substrate for ATP production because it is 
more efficient oxygen-wise (for more details on this 
topic refer to the review by Cheng et al16). Therefore, 
by switching substrate utilization to glucose oxida-
tion, ranolazine may provide a non-hemodynamic 
mechanism for preserving cardiac myocytes dur-
ing ischemia and reperfusion injury. It is not clear 
how ranolazine promotes glucose oxidation, but in 
perfused guinea pig hearts subjected to low-flow 
ischemia it was shown that ranolazine increased the 
amount of active dephosphorylated pyruvate dehy-
drogenase15 which is thought to play a key role in 
determining the rate of carbohydrate utilization.17,18
ranolazine as a late Na+ current inhibitor
The effect of ranolazine as a modulator of metabo-
lism occurs at concentrations greater than 10 μM. 
However, ranolazine exerts its effects as an anti-
anginal drug at lower concentrations, ie, 2–6 μM.19 
This implies that a mechanism other than promot-
ing glucose oxidation is probably responsible for the 
anti-anginal characteristics of ranolazine. Indeed, in 
a comprehensive study19 it was shown that ranola-
zine produces several ion channel effects. Of particu-
lar interest was the inhibitory effect of ranolazine on 
the late Na+ current (INa
L
) with an IC50 = 5.9 μM.19 
This inhibitory effect was also observed in other 
studies in which the INa
L
 was pharmacologically 
induced by the Anemonia sulcata toxin (ATX)-II.20,21 
A later study showed that ranolazine blocked both 
the peak Na+ current (INa) and the INa
L
 with a 
nine-fold selectivity for INa
L
 vs. INa,22 and that this 
blockade occurred at the same binding site where 
other local anesthetics, such as lidocaine, interacts 
with Na+ channels. Although the inhibitory effect of 
ranolazine on Na+ current and especially on the INa
L
 
may suggest an anti-arrhythmic effect, it could also 
explain its mechanism as an anti-anginal drug on the 
basis of preventing Na+ overload and the subsequent 
increase in intracellular Ca2+.
Cytosolic Ca2+ overload is a key event in the injury 
sustained during ischemia. It occurs due to activation 
of the Na+/Ca2+ exchanger in the reverse mode as a 
result of the increase in cytosolic Na+ which results 
from impaired Na+/K+ ATPase pump activity, coupled 
with an increased pH gradient between the intracel-
lular and extracellular spaces and concomitant acti-
vation of the Na+/H+ exchanger.23 However, increased 
cytosolic Na+ may also arise in part from activation 
of the INa
L
 by toxic ischemic metabolites24,25 and by 
Aldakkak et al
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reactive oxygen species that are generated during 
reperfusion.26 Thus ranolazine, an inhibitor of INa
L
, 
could reduce cytosolic Na+ during ischemia and sub-
sequently reduce cytosolic Ca2+. Indeed, Song et al27 
reported that ranolazine attenuated H2O2-induced 
intracellular Na+ and Ca2+ overload in rabbit isolated 
ventricular myocytes. We also showed that ranola-
zine reduced cytosolic Ca2+ in intact beating guinea 
pig hearts undergoing global no flow ischemia, and 
that this led to a decrease in mitochondrial Ca2+ over-
load and reactive oxygen species generation during 
ischemia.28 These effects of ranolazine on mitochon-
dria may underlie, in part, its cardio-protective effects 
against ischemia. What remains unclear is the exact 
mechanism by which ranolazine inhibits INa
L
.
Recent studies have focused on the pore-forming 
subunit of the cardiac Na+ channel, Nav1.5, which is 
the main ion channel that conducts Na+ in cardiac cells. 
One interesting study showed mechano-sensitive prop-
erties for INa in isolated mouse cardiomyocytes.29 This 
implies that the function of Nav1.5, among many other 
described regulatory mechanisms, is also modulated 
by the mechanical stretch of the membrane in which 
it is embedded. However, and more importantly, the 
novelty of the study came from the finding that rano-
lazine inhibited the mechano-sensitivity of Nav1.5 in 
a dose dependent manner, and that this inhibition did 
not require the established binding site. This study also 
suggested that it is only the neutral form of ranolazine 
that is capable of inhibiting the mechano- sensitivity 
of Nav1.5, thus leading the authors to speculate that 
ranolazine obtains access to the channel by partition-
ing within the lipid bilayer of the cell membrane. 
 Ranolazine inhibited the mechano-sensitivity of 
Nav1.5 with an IC50 = 54 μM which is about 10-fold 
higher than the therapeutic concentration.  Nonetheless, 
the authors suggest two reasons not to dismiss 
these findings. First, the results were obtained in an 
experimental model that does not mimic exactly the 
true mechanical environment of the channels in situ 
where other mechano-relevant elements likely medi-
ate the mechano-sensitivity of the Nav1.5. Second, 
ranolazine inhibits the mechano-sensitivity of Nav1.5 
by partitioning into the bilayer hydrophobic core29 in 
its neutral (effective) form. However, this partition-
ing increases with increasing temperatures and since 
the experiments were conducted at room tempera-
ture, one can expect that the effective membrane 
 concentration of ranolazine will increase at the higher 
physiological temperatures of the clinical setting.
ranolazine and mitochondrial complex I
As mentioned earlier, the effect of ranolazine as a 
metabolic modulator is probably related to increasing 
the amount of the active dephosphorylated pyruvate 
dehydrogenase. It is worth noting, however, that the 
pyruvate dehydrogenase complex is exclusively intra-
mitochondrial in mammalian tissues, which may 
suggest that ranolazine has another site of action that 
is intra-mitochondrial.8 Interestingly, Wyatt et al30 
showed that ranolazine inhibited mitochondrial 
respiration of NADH-linked substrates and that this 
was due to inhibition of the mitochondrial electron 
transport chain at the level of complex I. Furthermore, 
the inhibition by ranolazine resembled that of rotenone 
and amobarbital which are specific complex I blockers. 
The significance of this is that inhibiting complex I 
with amobarbital was protective against ischemic 
injury as we and others have shown.31,32 We postulated 
that inhibiting complex I during ischemia decreases 
electron transfer from complex I to complex III, 
thereby reduces electron leak, and superoxide (O2
•−) 
generation at complex III during late ischemia. So, 
if ranolazine inhibits complex I in a manner similar 
to that of rotenone and amobarbital, then it could 
very well promote its anti-anginal effect in part by a 
mitochondrial mediated mechanism, which involves 
the reduction in reactive oxygen species generation 
during ischemia and subsequently on reperfusion.
Indeed, ranolazine was shown to reduce reactive 
oxygen species generation during ischemia.28 Fur-
thermore, in a recent study Gadicherla et al showed 
that in hearts exposed to global ischemia, the addition 
of ranolazine on reperfusion improved mitochondrial 
complex I activity, restored electron transfer through 
Fe-S clusters of complex I, and preserved supercom-
plex assembly and cardiolipin integrity.33 However, 
there was no evidence that these observations were 
due to direct effects of ranolazine on complex I or 
even on mitochondria. Therefore, it was concluded 
that ranolazine indiscriminately reduced oxidative 
damage to complex I and its supportive structures and 
thus maintained optimal electron flow through com-
plex I and reduced the tendency for electron leak and 
the subsequent generation of O2
•−. It is important to 
mention that in the study by Wyatt et al30 ranolazine 
ranolazine and chronic stable angina
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was shown to be a weak inhibitor of complex I when 
compared with rotenone or amobarbital, especially 
in energetically coupled mitochondria. However, in 
uncoupled or broken mitochondria (sub-mitochon-
drial particles) ranolazine exerted a more potent 
inhibitory effect on complex I. The authors suggested 
that this inhibitory effect by ranolazine occurred 
because of the lower membrane potential in uncou-
pled mitochondria coupled with a more acidic envi-
ronment which favors greater protonation and uptake 
of ranolazine, or that it is only the charged form of 
ranolazine that is inhibitory. Nonetheless, regardless 
of the conditions of energisation of the mitochondrial 
inner membrane, the IC50 for inhibition of mitochon-
drial complex I by ranolazine was much higher than 
its therapeutic concentrations.
Ranolazine modulates myofilaments 
Ca2+ sensitivity
The general consensus so far is that ranolazine acts 
as an anti-anginal and anti-ischemic drug primarily 
by inhibiting INa
L
. In doing so, ranolazine prevents 
cytosolic Na+ overload and the subsequent excess in 
cytosolic Ca2+. The increase in cytosolic Ca2+ plays 
a key role in ischemic injury by causing mitochon-
drial Ca2+ overload, which then triggers a cascade 
of events that eventually leads to apoptosis/ necrosis 
and cell death.34,35 Increase in cytosolic Ca2+ may 
induce damage by non-mitochondrial mechanisms 
such as by activating Ca2+-dependent phospholipases 
and proteases with the subsequent loss of structure 
and function of the myocyte.36 Ca2+ also may induce 
diastolic dysfunction which leads to a sustained con-
tracture during diastole, an increase in myocardial O2 
consumption and compression of intramural small 
vessels, thus reducing nutritive blood flow to the isch-
emic territory.37 Interestingly ranolazine was found to 
attenuate the diastolic dysfunction in several animal 
studies38–43 and in human studies.44,45 While ranola-
zine may reduce diastolic dysfunction by inhibiting 
INa
L
 and the subsequent increase in cytosolic Ca2+, a 
very recent study may shed some light on a different 
mechanism for ranolazine.
In this study,46 the authors used a hypertensive 
mouse model (deoxycorticosterone acetate [DOCA]-
salt) of diastolic dysfunction. It is important to men-
tion that, in this study, no INa
L
 was noted, nor were 
there changes in Ca2+ cycling to indicate significant 
alterations in Ca2+ handling in this form of diastolic 
dysfunction. Yet ranolazine was effective in abating 
this form of diastolic dysfunction. Myofilaments iso-
lated from mice with diastolic dysfunction exhibited 
increased maximal tension and sensitivity to Ca2+ as 
well as a slowing of cross-bridge exit kinetics com-
pared with sham mice, and these changes were nor-
malized with ranolazine treatment. This suggested 
that ranolazine improved diastolic function at the 
cardiomyocyte level through the modulation of myo-
filament cross-bridge kinetics and sensitivity to Ca2+. 
Additionally, ranolazine, acting directly on myofila-
ments, improved diastolic dysfunction in the DOCA-
salt sensitive mice with the same concentrations used 
clinically with no significant effects on hemodynamic 
parameters. The results obtained from the DOCA-salt 
sensitive mice may not be transferable to humans. 
Nonetheless, the finding of this study may hint to a 
new possible mechanism of ranolazine as an anti-
anginal drug which deserves further exploration.
Clinical Studies
Several clinical trials have studied the effects of 
ranolazine in patients with coronary heart disease. 
Of these, three major trials focused on the role of 
ranolazine in treating chronic stable angina and one 
trial study focused on the role of ranolazine in treat-
ing acute coronary syndrome. A recent clinical trial 
focused on the role of ranolazine in PCI, and one more 
study assessed the cost of using ranolazine. There are 
no further studies assessing the effects of ranolazine 
on cardiovascular morbidity in patients with chronic 
angina. These studies are summarized below.
MArISA trial
Before the MARISA (Monotherapy Assessment of 
Ranolazine In Stable Angina) trial, clinical studies 
focused on the immediate release formulation of rano-
lazine in combination with other anti-anginal drugs. 
The MARISA trial was the first study to focus on the 
sustained release formulation of ranolazine as a sole 
treatment for angina. The purpose of the study was 
to compare, in a dose dependent manner, the effects 
of the sustained release formulation of ranolazine on 
treadmill exercise performance and to provide long-
term survival data in patients who completed the trial.10 
In this study, 191 patients with documented CAD and 
treated with anti-anginal drugs were enrolled. These 
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patients had to discontinue their anti-anginal treatments 
during the study except for sublingual nitroglycerin as 
needed. Randomized patients received a double-blind 
treatment with the sustained release formulation of 
ranolazine at doses of 500, 1000, and 1500 mg or a 
placebo, each administered twice daily for one week, 
according to a four-period, balanced Latin Square 
crossover design. At the end of each treatment period, 
exercise treadmill tests were performed at 4 h (peak) 
and later at 12 h (trough) after dosing. Compared 
to placebo, treatment with ranolazine significantly 
improved total exercise duration, time to angina, and 
time to 1 mm ST-segment depression at both peak 
and trough time points in a dose dependent manner 
(Fig. 1). Increase in ranolazine plasma concentrations 
was associated with an increase in mean exercise dura-
tions, but the increase in exercise duration appeared to 
plateau at the higher ranolazine concentrations.  Further 
analysis showed that gender, age, diabetes, and prior 
history of heart failure did not significantly modify 
the treatment effects of ranolazine. Some patients 
from the MARISA trial were still receiving ranolazine 
at one year and two years after their first doses. Their 
one-year and two-year survival rates on ranolazine 
were 96.3% and 93.6%, respectively. The MARISA 
study showed also that ranolazine was a safe drug 
with side effects usually occurring at higher dosage. 
Common side effects included constipation, nausea, 
dizziness, and asthenia. Ranolazine also prolonged 
the corrected QT (QTc) interval in a dose dependent 
 manner. In summary, the MARISA trial showed that 
ranolazine is an effective and safe drug when used 
alone as an anti-anginal treatment.
CArISA trial
The purpose of the CARISA (Combination Assessment 
of Ranolazine In Stable Angina) trial was to assess 
the anti-anginal and anti-ischemic effects of rano-
lazine in symptomatic chronic angina patients with 
severe CAD when combined with standard doses of a 
typical anti-anginal drug, ie, atenolol, amlodipine, or 
diltiazem.9 The efficacy end points included treadmill 
exercise duration, time to angina, time to 1 mm ST-
segment depression at peak and trough, and the num-
ber of angina attacks and  sublingual  nitroglycerin uses 
reported by the patients. In this study, 823 patients 
were assigned randomly to receive placebo, 750 mg 
ranolazine, or 1000 mg ranolazine twice daily for 
12 weeks in addition to receiving another typical 
anti-anginal drug. The major finding was that ranola-
zine at the two doses significantly increased exercise 
duration at both the trough and the peak concentra-
tions (Fig. 2). More importantly, treatment with the 
other anti-anginal drugs did not significantly modify 
the response to ranolazine. Ranolazine decreased 
the number of angina attacks and subsequently it 
decreased nitroglycerin consumption (Fig. 3). Some 
patients from the CARISA trial were still receiving 
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Figure 1. Summary of the effects of three doses of ranolazine on  exercise 
treadmill test parameters.
Notes: values shown represent difference from placebo in seconds. 
Data are mean ± standard error. *P , 0.05 in treatment with ranolazine 
vs. placebo. b.i.d. = twice daily.
ranolazine and chronic stable angina
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increases in QTc interval. In summary, the CARISA 
trial showed that ranolazine can provide an additional 
anti-anginal effect in patients treated with the classi-
cal anti-anginal drugs.
ErICA trial
Prior to the ERICA (Efficacy of Ranolazine In Chronic 
Angina) trial, ranolazine was shown to be effective as 
an anti-anginal treatment when used alone or in com-
bination with other anti-anginal drugs at sub-maximal 
dosage, but its efficacy when combined with a maxi-
mum recommended dosage of another conventional 
anti-anginal treatment had not been investigated. 
Therefore, the goal of the ERICA trial was to deter-
mine if ranolazine could reduce angina in patients with 
persistent angina despite treatment with the maximal 
recommended daily dosage of amlodipine.14 The effi-
cacy of ranolazine was assessed by the weekly aver-
age frequency of angina episodes, the average weekly 
nitroglycerin consumption rate, and the change from 
baseline of the 5 dimensions of the Seattle Angina 
Questionnaire (SAQ). Safety was assessed by evalu-
ating reported adverse effects, hemodynamics, labo-
ratory measures, and ECG. In this study, 565 patients 
with $3 episodes of angina per week were receiv-
ing a maximum dosage of amlodipine at 10 mg/day. 
In addition to amlodipine, patients were randomized 
to also receive either 1000 mg ranolazine or placebo 
twice daily for 6 weeks. Adding ranolazine reduced 
the weekly rate of angina episodes (Fig. 4A), and it 
reduced the average weekly rate of nitroglycerin con-
sumption (Fig. 4B), but it improved only the angina 
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Figure 2. Summary of the effects of two doses of ranolazine on exercise 
treadmill test parameters.
Notes: values shown represent difference from baseline values in 
seconds. placebo indicates treatment only with another anti-anginal 
drug (atenolol 50 mg, amlodipine 5 mg, diltiazem 180 mg). Data are 
mean ± standard error. *P , 0.05 in treatment with ranolazine vs. 
placebo. b.i.d. = twice daily.
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Figure 3. Summary of the effects of two doses of ranolazine on number 
of angina attacks per week.
Notes: placebo indicates treatment only with another anti-anginal 
drug (atenolol 50 mg, amlodipine 5 mg, diltiazem 180 mg). Data are 
mean ± standard error. *P , 0.05 in treatment with ranolazine vs. 
placebo. b.i.d. = twice daily.
ranolazine at one year and two years after their first 
doses. Their one-year and two-year survival rates on 
ranolazine were 98.4% and 95.9%, respectively. As 
in the MARISA trial, common side effects included 
constipation, nausea, dizziness, and asthenia with 
very few patients using 1000 mg ranolazine reporting 
episodes of syncope. Ranolazine also caused small 
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frequency dimension of the SAQ. The treatment effect 
of ranolazine in different subgroups was numerically 
similar to that in the population as a whole (Fig. 5), 
however the study was not powered to test the treat-
ment effects within subgroups. Ranolazine did not 
induce any significant changes in heart rate or blood 
pressure when compared to placebo. The adverse 
effects occurred in 35.3% of amlodipine+placebo- 
and 39.9% of amlodipine+ranolazine-treated patients 
with women and patients older than 65 reporting 
more adverse effects. In summary, the ERICA trial 
demonstrated that ranolazine provided additional 
anti-anginal benefit in patients who remained symp-
tomatic despite being treated with the maximal dosage 
of the Ca2+ channel blocker amlodipine.
MErLIN-TIMI 36 trial
The goal of the MERLIN (Metabolic Efficiency with 
Ranolazine for Less Ischemia in Non-ST-Elevation 
Acute Coronary Syndrome)-TIMI 36 trial was to 
 evaluate the efficacy and safety of ranolazine in the 
short and long term in patients with acute coronary 
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syndromes who were also receiving standard therapy.47 
The primary efficacy end point was a composite of 
cardiovascular death, myocardial infarction, or recur-
rent ischemia through the end of the study. The major 
safety end points were assessed as death from any 
cause and the incidence of symptomatic documented 
 arrhythmia. In this study, 6560 patients who were 
receiving standard treatment for non-ST elevation 
ranolazine and chronic stable angina
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acute coronary syndrome were also randomized to 
additionally receive ranolazine or placebo. Ranola-
zine 200 mg (or matching placebo) was given first 
intravenously within 1 h followed by slower intra-
venous infusion over the next 12–96 h. Then, rano-
lazine extended-release (or matching placebo) tablet 
was given orally at a dose of 1000 mg twice daily for 
the remainder of the study (up to 24 months with a 
median of 348 days). Ranolazine did not reduce the 
rate of cardiovascular death, myocardial infarction, 
or recurrence of ischemia (ranolazine 21.8% vs. pla-
cebo 23.5%, P = 0.11), all considered as the primary 
endpoints of the study. However, the effect of long 
term treatment with ranolazine on angina was evident 
as it reduced worsening angina (ranolazine 4.2% vs. 
placebo 5.9%, P = 0.02). Moreover, an increase in 
or addition of an anti-anginal drug was less frequent 
(ranolazine 10.6% vs. placebo 13%, P = 0.003). There 
was no significant heterogeneity in the effect of rano-
lazine on the primary endpoints across the major sub-
groups examined. Death from any cause did not differ 
among patients treated with ranolazine compared with 
patients treated with placebo. The incidence of symp-
tomatic documented arrhythmias throughout the dura-
tion of the study was similar in patients treated with 
ranolazine compared with placebo. However, the fre-
quency of clinically significant arrhythmias observed 
during Holter monitoring during the first 7 days was 
lower in the ranolazine group vs. in the placebo group. 
Adverse events (dizziness, nausea, constipation, syn-
cope) were more frequent with ranolazine vs. placebo. 
In summary, this study showed no significant benefit of 
ranolazine compared with placebo with respect to the 
primary efficacy endpoints. Also, ranolazine appeared 
to be safe but with no difference from placebo with 
respect to the safety endpoints.
role of ranolazine during percutaneous 
coronary intervention
Myocardial injury may occur in patients undergoing 
PCI and this may lead to higher mortality. Therefore, 
the goal of this study was to determine if pretreat-
ment with ranolazine before PCI has any protective 
role on periprocedural myocardial damage.48 The 
primary endpoint was defined as the postprocedural 
increase in creatine kinase-MB (CK-MB) $3 times 
of the upper limit of normal indicating  periprocedural 
myocardial damage. Other cardiac markers such as 
Troponin I and myoglobin levels were also measured. 
In this study, 70 patients who fulfilled the inclusion 
criteria and scheduled for elective PCI were included 
and randomly divided into two groups, 35 patients 
each. One group received placebo while the other 
received ranolazine 1000 mg twice daily for 7 days 
before the planned intervention. Ranolazine reduced 
the periprocedural myocardial infarction (ranolazine 
6% vs. placebo 22%, P = 0.041), which is the pri-
mary endpoint. Overall, there were fewer patients in 
the ranolazine group compared to the placebo group 
that showed increases above the upper limit of nor-
mal in CK-MB (ranolazine 23% vs. placebo 40%, 
P = 0.01), troponin I (ranolazine 31% vs. placebo 
48%, P = 0.011), and myoglobin (ranolazine 28% 
vs. placebo 43%, P = 0.033). Further, ranolazine 
reduced the incidence of death, myocardial infarc-
tion, or target-vessel revascularization at 30 days 
after the procedure (ranolazine 9% vs. placebo 28%, 
P = 0.03), but this was mainly influenced by the 
periprocedural events because when periprocedural 
infarctions were not counted there was no signifi-
cant difference between the two groups (ranolazine 
3% vs. placebo 6%, P = 1). In summary, this study 
showed that pretreatment with ranolazine is effective 
in decreasing the incidence of myocardial infarction 
during PCI.
Costs and clinical outcome
Ranolazine per dose is more expensive than the other 
traditional anti-anginal treatments. However, the focus 
should be on total costs of care and not on the cost of 
single treatment. Although some studies analyzed the 
costs for treating angina, the study by Phelps et al49 
was the first chronic angina medication-specific cost 
comparative study. In this study, a large managed care 
administrative claims database was analyzed to bet-
ter understand the effect of ranolazine versus alterna-
tive anti-anginal drugs on health care use and total 
costs of care. Specifically, the primary dependent 
variables for this study were total costs of care and 
rate of revascularization procedures and services. A 
retrospective administrative claims-based analysis 
from a large, geographically diverse US health insur-
ance plan with 11.2 million commercial enrollees 
was performed. First, patients who were identified 
to have angina were selected. Then of these, only 
patients who were prescribed a new anti-anginal drug 
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(index event) that was not used within the previous 
6 months (pre-index period) and continued using the 
new treatment for 6 more months (post-index period) 
were selected. This was to insure that only patients 
who had uncontrolled angina or had side effects that 
required their physician to alter their medication plan 
were enrolled. After further exclusion, 4545 patients 
were left for final analysis and were divided into 
3 groups. Newly prescribed ranolazine, long acting 
nitrates, or β-blockers/Ca2+ channel blockers. In the 
6 months pre-index period, there were no significant 
differences among all groups in total costs of care 
and in the rates of revascularization. Interestingly, 
even though ranolazine is more expensive per dose 
than the other anti-anginal drugs, the unadjusted total 
costs of care were lower for ranolazine than for the 
other groups. This is likely a result of fewer hospi-
talizations in patients treated with ranolazine com-
pared to the other non-ranolazine treated groups. The 
ranolazine treated group also had significantly lower 
revascularization rates in the 6 months post-index 
period. Furthermore, a multivariate analysis was per-
formed to control for differences in age, gender, and 
presence of co-morbid conditions that can affect total 
costs of care. But even then, the adjusted total costs 
of care and revascularization rates were significantly 
lower in the ranolazine treated group compared to 
the other non-ranolazine treated groups. Therefore, it 
was concluded that adding ranolazine to the therapy 
of patients with poorly controlled angina could lead 
to better outcome and lower costs compared with the 
other alternatives. These finding are all summarized 
in Table 2.
safety
From all the 4 major clinical trials, ranolazine, at any 
dose, did not induce clinically significant changes in 
heart rate or blood pressure during rest or exercise. 
Overall, the side effects event rate increased with higher 
doses. The most common side effects of ranolazine 
are dizziness, nausea, vomiting, constipation, head-
ache, and asthenia. However, all these side effects are 
mild to moderate in general, occur soon after using the 
drug, and reverse promptly with reducing the dose or 
discontinuation of treatment.50 The increase in adverse 
events seen with the 1500 mg dose in MARISA is dis-
proportionately larger than the increase in anti-anginal 
efficacy; thus, the 1500 mg twice-daily dose is not rec-
ommended for clinical use. Postural hypotension and 
syncope were observed in a small number of patients 
taking $ 1000 mg ranolazine, most likely due to con-
comitant usage of other medications that are vasoac-
tive or known to increase the plasma concentration of 
ranolazine. However, this can be prevented by starting 
ranolazine at a low dose (500 mg) and slowly increas-
ing the dose as needed. Ranolazine may cause some 
small changes in laboratory parameters such as an 
increase in eosinophil count, an increase in creatinine, 
a decrease in hematocrit, and a decrease in hemoglobin 
A
1C
 in diabetic patients. Ranolazine may prolong the 
QTc interval in a dose dependent manner,
9,10 therefore 
it is recommended to avoid ranolazine in patients with 
Table 2. A summary of the differences between ranolazine and the other traditional anti-anginal drugs in total costs of care 
and rate of revascularization in the pre- and post-index period. 
Ranolazine  
(n = 881)
Nitrates  
(n = 1788)
β blockers/Ca2+ channel  
blockers (n = 1876)
pre-index total cost $ 19199 19841 
(P = 0.603 vs. ranolazine)
18152 
(P = 0.410 vs. ranolazine)
% pre-index revascularization 24.97 26.51 
(P = 0.394 vs. ranolazine)
25.16 
(P = 0.915 vs. ranolazine)
Unadjusted post-index total cost $ 14781 17773 
(P = 0.022 vs. ranolazine)
16785 
(P = 0.120 vs. ranolazine)
% unadjusted post-index  
revascularization
9.88 20.25 
(P , 0.001 vs. ranolazine)
15.51 
(P , 0.001 vs. ranolazine)
adjusted post-index total cost $ 13961 18166 
(P , 0.001 vs. ranolazine)
17612 
(P = 0.002 vs. ranolazine)
% adjusted post-index  
revascularization
9.9 20.4 
(P , 0.001 vs. ranolazine)
15.4 
(P , 0.001 vs. ranolazine)
Table assembled from phelps et al. Clinical Therapeutics/volume 34, Number 6, 2012.
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known long QTc and in patients taking drugs that may 
prolong QTc.
Ranolazine is metabolized primarily in the liver by 
the enzyme CYP3A4, therefore caution should be taken 
in those who use other drugs that are known to interact 
with this enzyme or in patients with hepatic dysfunc-
tion as this may cause accumulation of  ranolazine.51 
Furthermore, ranolazine is cleared mainly by the kid-
neys and so careful dose titration is recommended 
in patients with mild to moderate renal impairment, 
whereas it is completely contraindicated in patients 
with severe renal impairment.52 Ranolazine is trans-
ported by P-glycoprotein7 and therefore it must be used 
cautiously with drugs that inhibit P-glycoprotein such 
as verapamil, as this may increase the absorption and 
subsequently the plasma concentration of ranolazine.
Efficacy
Early on, ranolazine was manufactured in an immedi-
ate release form and several clinical trials tested its 
efficacy for the treatment of chronic angina.11–13,53,54 
These trials yielded results ranging from negative 
effects to studies showing benefits of ranolazine as 
an anti-anginal treatment. This range of effects likely 
stems from the different dosages utilized. Eventually, 
the immediate release form was replaced by the more 
favorable extended (sustained) release form which is 
now commercially available for treatment. The effi-
cacy of this formulation was evaluated in the 4 large 
clinical trials summarized above.9,10,14,47 MERLIN-
TIMI 36 was the only study to assess the efficacy of 
the extended formulation of ranolazine for treating 
non-ST-elevation acute coronary syndrome and it 
showed no benefit for ranolazine in this population. 
However, the other three studies (MARISA, CARISA, 
ERICA) demonstrated beneficial effects of ranolazine 
in treating chronic angina. For example, ranolazine 
alone (MARISA) increased the treadmill exercise 
performance similar to that observed with other anti-
anginal drugs.55,56 However, when ranolazine was 
combined with other anti-anginal drugs in some tri-
als (CARISA, ERICA), the beneficial effects of rano-
lazine seemed initially limited, ie, it reduced angina 
episodes by nearly 1 per week, and it increased exer-
cise duration by nearly 24–34 s at trough concentra-
tions (MARISA) compared to placebo.  Nonetheless, 
one cannot underestimate these findings because a 
small increase in exercise duration translates into the 
ability of patients to carry on more daily living activi-
ties without being symptomatic. Therefore, and based 
on these findings, it is safe to say that ranolazine is 
recommended for the therapy of chronic angina as the 
sole drug, or combined with other treatments.
Patient Preference
Based on federal published guidelines, pharmacological 
management of chronic angina includes using short 
acting nitrates for treating the episode of angina, and 
then combined treatment with long acting nitrates, 
β-blockers, and Ca2+ channel blockers.57 As an 
alternative, ranolazine can also be used by itself or in 
combination with other anti-anginal drugs. Each one 
of these drugs has its share of side effects. Ranolazine, 
however, is the exception in that it brings about its anti-
anginal effects without significant clinical changes in 
hemodynamics (blood pressure, heart rate). Therefore, 
it may be well suited for patients with lower blood 
pressures or heart rates in whom the addition or the 
gradual increase in the dose of anti-anginal drugs with 
important hemodynamic effects may not be tolerated.9 
Moreover, ranolazine was shown to have anti-
arrhythmic58 and anti-diabetic effects.59 The latter is 
of a particular interest since many patients who suffer 
from chronic angina already have diabetes mellitus. 
Ranolazine in fact was shown to reduce HbA
1C
 in 
patients with diabetes mellitus and to possibly mitigate 
new hyperglycemia in patients at risk for diabetes 
mellitus. These findings make ranolazine an attractive 
anti-anginal treatment for patients with chronic angina 
and impaired glucose metabolism.59
Ranolazine costs considerably more than the other 
anti-anginal drugs per dose. However, and as discussed 
earlier, a comprehensive retrospective claims analy-
sis49 showed that adding ranolazine as a replacement 
for another ineffective anti-anginal drug was associ-
ated with lower rates of prescription fills for short act-
ing nitrates, reduced revascularization rates, and lower 
total cost of care greater than with other anti-anginal 
therapies (discussed above, see section Costs and Clin-
ical Outcome). Therefore, the associated reductions 
in non-pharmacy costs of care when using ranolazine 
more than offset the higher prescription drug costs.49
Place in Therapy
The FDA approved the use of ranolazine as a 
first line drug for the treatment of chronic angina. 
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 However, the European Society of Cardiology (ESC) 
still recommends using ranolazine as an add-on ther-
apy or as a substitution therapy when conventional 
drugs are not tolerated.2 Recent guidelines from the 
American College of Cardiology Foundation and 
the American Heart Association (ACCF/AHA, etc) 
also recommends using ranolazine in circumstances 
in which other anti-anginal drugs are not adequately 
effective or are not tolerated.60 Specifically, rano-
lazine can be used to relieve symptoms in patients 
with stable ischemic heart disease in two cases: (1) 
as a substitute for β-blockers if initial treatment with 
β-blockers leads to unacceptable side effects or is 
ineffective or if initial treatment with β-blockers is 
contraindicated; (2) in combination with β-blockers 
if the initial treatment with β-blockers is not success-
ful. Ranolazine is available as extended-release tab-
lets at 500 mg and 1000 mg, and a recommendation is 
to start ranolazine at 500 mg twice daily and increase 
to 1000 mg twice daily, as needed, based on clini-
cal symptoms. The MERLIN-TIMI 36 trial showed 
no benefit of ranolazine in treating acute coronary 
syndrome; therefore ranolazine is not approved for 
treating these conditions. Clinical trials did not show 
significant differences in the efficacy of ranolazine 
between younger and older patients. However, older 
patients may have a greater frequency of decreased 
hepatic or renal function and therefore it is recom-
mended to start ranolazine at the lowest dosing range 
in this population. Ranolazine should not be used in 
patients with cirrhosis, severe renal insufficiency, 
preexisting long QTc, or in patients using drugs that 
are known to prolong QTc or inhibit CYP3A4.
Conclusions
Coronary heart disease remains a global malady 
despite the advancement in its management. Chronic 
angina is one manifestation of CAD. Traditional 
anti-anginal therapy includes drugs that decrease 
O2 demand and increase blood flow. Ranolazine, 
however, belongs to a different class of anti-anginal 
drugs. It antagonizes the disturbance in ion homeosta-
sis, specifically Na+ and subsequently Ca2+ that may 
occur during ischemia by inhibiting the INa
L
. Other 
possible mechanisms including its direct effect on 
cardiac myofilaments, or indirectly preserving mito-
chondrial complex I, may in part mediate its effects 
as an anti-anginal drug. Although ranolazine is more 
expensive than other traditional treatments per dose, 
it actually cuts the non-pharmacy costs of care in the 
long run. However, it remains important to compare 
total costs of care of ranolazine with the other anti-
anginal drugs when ranolazine is used as a new, first 
line, anti-anginal drug and not only as an alterna-
tive therapy when the other treatments fail to control 
angina. Clinical trials showed ranolazine to lack many 
of the hemodynamic side effects observed with the 
other anti-anginal drugs, and more importantly to be 
an effective anti-anginal treatment when used alone 
or in combination with other conventional treatments. 
Yet, a direct comparison between ranolazine and the 
other conventional anti-anginal drugs (β-blockers, 
Ca2+ channel blockers, nitrates) is warranted before 
ranolazine can seriously be recommended as a first 
line therapy for chronic angina.
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